Favorable Survival Outcomes in Epidermal Growth Factor Receptor (Egfr)-Mutant Non-Small Cell Lung Cancer Sequentially Treated with a Tyrosine Kinase Inhibitor and Osimertinib in a Real-World Setting
Journal of Cancer Research and Clinical Oncology(2023)
Key words
Sequential therapy,Osimertinib,Rebiopsy,EGFR-mutated NSCLC,EGFR T790M mutation,Second line
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined